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This study was done to determine the time while the binary admixtures with midazolam and 
haloperidol drugs are administered by perfusion to the patients in the clinical routine. Samples with 
different concentrations of both drugs were prepared following the usual clinical practice. Solvents 
used were 0.9 % sodium chloride solution and 5% dextrose, and viaflo plastic bags were used as the 
containers of the admixtures. Samples were not protected from light and were stored at 20 ºC or at 4 ºC. 
Compatibility and physicochemical stability were studied by visual inspection, turbidity measurement, 
pH determination and ultraviolet detection high performance liquid chromatography (UV-HPLC) was 
used to determine midazolam and haloperidol concentrations. The assay was validated following the FDA 
and EMA guidelines. Darunavir was used as internal standard (IS). For the studied admixtures, turbidity 
measurements and pH determinations showed little changes in function of the time. Haloperidol and 
midazolam concentrations determined by HPLC are within the acceptable range of drug concentrations, 
which are considered stable for four days in case of admixtures stored at 20 ºC and for seven days for 
refrigerated admixtures. Taking into account the microbiological risk matrix, the compatibility and 
the chemical and microbiological stability of the midazolam and haloperidol in the co-administered 
admixtures in viaflo plastic bags with 0.9 % sodium chloride solution and 5% dextrose can be set as 48 
hours when samples are stored at 20 ºC and one week if they are refrigerated.
Keywords: Midazolam/pharmacology. Haloperidol/pharmacology. HPLC/methods. Additives in 
Sanitizing Products. Chemical stability. Physical stability. Physicochemical properties.
INTRODUCTION
Sedation is understood in the palliative care context 
as a deliberate administration of drugs in the required 
doses and combinations to reduce patient’s awareness 
with advanced or terminal disease (De Graeff, Dean, 
2007). The most frequent indication of terminal sedation 
is the presence of refractory symptoms such as dyspnea, 
delirium, pain and psychological distress. Pharmacological 
treatment will depend on the detected refractory symptom.
Drug stability studies are needed when they could be 
administered together at ambient temperature for parenteral 
dosage. Furthermore, the influence of the material were 
the solutions are contained has to be taken into account. 
The currently employed materials for clinical use such as 
glass or plastics as PVC, PP or elastomer material and their 
influence in the stability of the drugs are usually studied. 
Additionally, stability can be different when different 
concentrations of the drugs are employed. Then, the study of 
the stability has to include the expected concentrations in the 
clinical use (Trissel, 1983). Usually, the chemical stability 
of a drug is acceptable when the amount of the drug is from 
90% to 110% of the initial value (Jenke, 1996).
Midazolam is the most used drug in palliative 
sedation and it is considered as first-line drug (De Graeff, 
Dean, 2007; Rosengarten et al., 2009). In palliative care 
units, its use as a sedative reaches 93 to 98% of the patients 
(Krakauer et al., 2000; Elsayem et al., 2009). This drug is 
a water-soluble benzodiazepine and it has a short plasma 
half-life, an important factor especially in intermittent 
sedation, and its subcutaneous onset of action is 5-10 
minutes (Midazolam, 2003). The recommended dose is 
easily titrated; in fact, it can be started with a dose between 
0.5 mg/h and reach a usual effective dose of 1-20 mg/h 
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(Cherny, Radbruch, 2009). It is a drug that can be combined 
with other medications used in palliative care and it can 
be administered intravenously and subcutaneously (online 
Palliative Care Formulary, 1991). This benzodiazepine 
is, with haloperidol, the usual election in the delirium 
treatment and is used stepwise to improve the patient’s 
symptomatology. Midazolam chemical stability has been 
described with other drugs as morphine (LeBelle, Savard, 
Gagnon, 1995), fentanyl (Wilson, Schneider, Ravenscroft, 
1998) or with diamorphine (Allwood, Brown, Lee, 1994).
Haloperidol is a butyrophenone and it is the 
antipsychotic usually employed in the treatment of the 
delirium (Porta et al., 2004) by its higher potency and 
lower secondary effects than the rest of the neuroleptic 
drugs. Haloperidol may also be administered intravenously 
and subcutaneously wherein low doses usually are 
required (1-10 mg/day) (Haloperidol, 2017; Hui et al., 
2010). Its chemical stability has been described with other 
drugs such as morphine (LeBelle, Savard, Gagnon, 1995), 
tramadol (Negro et al., 2005), diamorphine hydrochloride 
(Collins et al., 1986) or hyoscine (Barcia et al., 2003). 
In addition, haloperidol and midazolam can be 
used under combination in the same perfusion solution 
over several days to treat the delirium in hospitalized 
terminal patients or patients with palliative care attended 
by the domiciliary hospitalization units. Therefore, these 
admixtures have to be prepared in advance, especially for 
outpatients under sedative treatment; and physicochemical 
stability of the admixtures should be studied in function 
of the concentration of the drugs, the type of diluent and 
the storage conditions (temperature and presence of light).
To the best of our knowledge, chemical stability 
of both drugs is not clearly described yet when they are 
co-administered in the same admixture. Martínez-Gómez 
et al. (2007) have described just one combination of 
haloperidol and midazolam with 0.21 and 0.63 mg mL-1, 
respectively. The authors have used 0.9 % sodium chloride 
solution and dextrose 5% as diluents and samples were 
stored at 24 ºC. The authors have not found any significant 
change (a loss higher of 10%) after fifteen days of storage.
Moreover, González-Valdivieso et al. (2009) have 
presented a description about the chemical stability of two 
ternary blends with haloperidol, midazolam and hyoscine 
butylbromide by using just 5% dextrose as diluent and 
storing the admixtures at room temperature. The studied 
concentrations were 0.2, 1.2 y 1.2 mg mL-1 and 0.8, 1.2 
y 1.2 mg mL-1 for haloperidol, hyoscine butylbromide 
and midazolam, respectively. Then, just a change in the 
concentration of haloperidol was taken into account. The 
authors have found a 72-hour stability for the studied 
concentrations.
The previously studied conditions do not cover the 
usual concentration range of both drugs in the clinical use. 
In palliative care, administered midazolam concentrations 
can be even ten times higher than haloperidol. 
T h e r e f o r e ,  a  t h o r o u g h  s t u d y  a b o u t  t h e 
physicochemical stability of these admixtures analyzing 
different levels of concentration, diluents and temperatures 
is needed to improve the clinical use of midazolam and 
haloperidol in palliative sedation.
MATERIAL AND METHODS
Material
Haloperidol, used as standard, was provided by 
Kern Pharma (Terrassa, Spain). Commercial samples of 
midazolam were acquired from Normon (Tres Cantos, 
Spain). Three different concentrations of midazolam were 
used to prepare the admixtures: 5 mg/5 mL (Lot #L1JE), 
15 mg/3 mL (Lot #1JB1) and 50 mg/10 mL (Lot #L0TR). 
Haloperidol 5 mg/1 mL (Lot #K10) commercial samples 
were purchased from Esteve (Barcelona, Spain). Janssen 
(Beerse, Belgium) has provided the internal standard 
darunavir. HPLC-grade solvents as acetonitrile and water 
were obtained from Teknokroma (Barcelona, Spain) 
and methanol was purchased from Merck (Darmstadt, 
Germany). KH2PO4 was acquired from Panreac (Barcelona, 
Spain). 0.9 % sodium chloride solution (Lot #17B10E4U) 
and dextrose 5% (Lot #17B01E4D) were purchased from 
Baxter (Ribarroja del Turia, Spain).
Methods
Turbidity measurement
Turbidity of the samples was measured via 
MicroScan Turbidity Meter of Siemens Healthcare 
Diagnostics (Camberley, UK) comparing with a blank 
sample of 0.9% sodium chloride solution or 5% dextrose in 
function of the diluent of each sample. The measurement 
was done at different times: 0, 24, 72, 96 and 168 hours.
pH determination
pH was measured in a pH500 pH meter from 
Hanna Instruments (Padova, Italy). Buffer calibration 
solutions were acquired to Hamilton Bonaduz (Bonaduz, 
Switzerland). The determination was done at 0, 24, 72, 96 
and 168 hours.
HPLC concentration drugs measurement
HPLC equipment was a Shimadzu LC-20AD pump 
with a DGU-20AS degasser and SIL-20AC autosampler, 
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an oven CTO-10AS and a UV detector SPD-M20A 
with a deuterium lamp and the selected wavelength 
was 254 nm. The employed column was a Tracer Excel 
120 ODSB (5 μm, 15x0.46 cm) with a mobile phase of 
a mixture with 0.037 M KH2PO4 buffer solution (pH 
4.3±0.1), acetonitrile and methanol (40:50:10, v/v) at 
a flow rate of 1.5 mL min–1. The volume of injection 
was 10 µL. Darunavir was used as internal standard at 
final concentration of 2.5 µg mL–1. The quantification of 
midazolam and haloperidol was done at the same time 
of pH determination and turbidity measurement: 0, 24, 
72, 96 and 168 hours.
Preparation of stock solutions, calibration 
standard and quality control samples
Samples were prepared using a stock solution 
of haloperidol in methanol (1.0 mg mL-1) and using 
commercial samples of midazolam 5 mg/5 mL. Stock 
solutions were stored protected from light at 4 ºC. Both 
were diluted each day ten times until 0.10 mg mL-1 to 
prepare eight calibrators in a linear range concentrations 
from 8 to 80 µg mL−1 in case of midazolam and from to 2 to 
12 µg mL−1 for haloperidol concentrations. Five calibration 
standards (n=5) and three quality control samples (n=3) 
were prepared. Internal standard darunavir was added 
from the stock solutions of 5000 µg mL−1 in methanol and 
diluting until a solution of 50 μg mL–1 of the IS was used 
to add 25 μL to each calibrator. The final volume of each 
calibrator was 500 μL, including the added haloperidol, 
midazolam and IS volume and filling with mobile phase.
Sample processing
Nine admixtures with midazolam and haloperidol 
were prepared. The content of ampoules of midazolam 
and haloperidol were added to the 0.9% sodium chloride 
solution (SF) or 5% dextrose (SG) in viaflo plastic bags that 
not protected from light. Different range of concentrations 
was taken into account. In case of haloperidol, 10 and 
20 mg were added, and for midazolam, concentrations 
were from 30 to 200 mg. All the prepared samples were 
homogenate by agitation of 30 s. Finally, seven of the 
studied admixtures were stored at room temperature 
(20 ºC) and two of them were refrigerated (4 ºC). The 
prepared admixtures are presented in Table I.
Compatibility determination
Compatibility was considered in the study of the 
apparition of turbidity, precipitate or colour change. The 
determination was done by visual inspection each day. 
Then, turbidity and pH were determined.
Validation of the analytical method
The analytical method was validated according to 
the guidelines of the agencies such as FDA (2001) and 
the European Medicines Agency (EMA) (2011). The 
studied parameters were specificity, selectivity, linearity, 
precision, accuracy, forced degradation studies and stock 
and working solutions stability. For more information, see 
the Supporting Information.
Applicability of analytical method
This assay was used to quantify the midazolam 
and haloperidol concentrations in perfusion solution. To 
determine this, 50 µL of each sample were added to 425 µL 
of mobile phase and 25 µL of the IS solution. The study 
was done until one week after the sample preparation. 
Studied times were 0, 24, 72, 96 and 168 hours.
TABLE I - Midazolam/haloperidol admixtures
Sample Haloperidol (mg) Midazolam (mg) Solution (mL) Temperature (ºC)
MIDHAL1 10 30 250 SF 20
MIDHAL2 10 100 250 SF 20
MIDHAL3 10 120 250 SF 20
MIDHAL4 20 100 250 SF 20
MIDHAL5 20 200 250 SF 20
MIDHAL6 10 30 250 SG 20
MIDHAL7 20 200 250 SG 20
MIDHAL8 20 200 250 SF 4
MIDHAL9 20 200 250 SG 4
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RESULTS
Visual inspection of the midazolam and haloperidol 
admixtures did not report any change about appearance, 
colour change or apparition of turbidity or precipitate. 
Turbidity measurement was done and the obtained results 
in function of the time and the total variance are presented 
in Table II.
Additionally, the pH values were determined in 
function of the time to evaluate a possible change in 
the admixtures. Table III collects the pH values for the 
admixtures at 0, 24, 72, 96 and 168 hours. This table also 
presents the variance between the maximum and minimum 
values.
Finally, the concentration of the drugs was measured 
by HPLC. The obtained results are presented in Table 
IV. In case of initial time (T=0), drugs are presented by 
their concentration. For the rest of the measurements, the 
remaining percentage is presented for each drug.
DISCUSSION
Recent study (Kotfis et al., 2017) exposed than 
midazolam is one of the most selected sedative drugs for 
more than 24-hour treatments and the preferred agent for 
delirium treatment was haloperidol. 
The use of different drugs under combination 
allows the administrations of smaller volumes, reducing 
the number of pumps and preventing stress on the veins. 
However, to know if an admixture with two or more drugs 
can be prepared, the physicochemical stability has to be 
studied (Estan-Cerezo et al., 2017). 
Sedatives are frequently used towards the end of life 
for delirium/agitation and even more in palliative patients 
who had significantly higher total daily midazolam doses 
days around death (Schildmann, 2018). For Martínez-
Gómez et al. (2007) who studied midazolam: haloperidol 
concentration ratio was 3:1; and González-Valdivieso et 
al. (2009) studied two ternary blends with a maximum 
TABLE II - Turbidity measurements in function of the time
Sample
Time (hours)
Variance
0 24 72 96 168
MIDHAL1 0.01 0.01 0.01 0.01 0.00 -0.01
MIDHAL2 0.04 0.03 0.00 0.02 0.02 -0.02
MIDHAL3 0.03 0.02 0.00 0.01 0.01 -0.02
MIDHAL4 0.02 0.03 0.02 0.00 0.01 -0.01
MIDHAL5 0.02 0.03 0.00 0.02 0.02 0.00
MIDHAL6 0.04 0.03 0.04 0.04 0.05 0.01
MIDHAL7 0.03 0.03 0.02 0.02 0.03 0.00
MIDHAL8 0.03 0.04 0.00 0.03 0.01 -0.02
MIDHAL9 0.05 0.03 0.05 0.04 0.04 -0.01
TABLE III - pH determinations in function of the time for the midazolam/haloperidol admixtures
Sample
Time (hours)
 Variance
0 24 72 96 168
MIDHAL1 3.67 3.65 3.62 3.64 3.67 0.05
MIDHAL2 3.50 3.46 3.44 3.46 3.44 0.06
MIDHAL3 3.49 3.46 3.45 3.46 3.46 0.04
MIDHAL4 3.43 3.40 3.40 3.38 3.41 0.05
MIDHAL5 3.30 3.30 3.31 3.31 3.30 0.01
MIDHAL6 3.67 3.67 3.60 3.65 3.62 0.07
MIDHAL7 3.39 3.33 3.27 3.26 3.33 0.13
MIDHAL8 3.39 3.36 3.34 3.35 3.38 0.05
MIDHAL9 3.31 3.30 3.28 3.32 3.33 0.05
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concentration ratio between them of about 6:1. In 
palliative care, administered midazolam concentrations 
can be even ten times higher than haloperidol like the 
concentrations analyzed in our study (midazolam: 
haloperidol concentration ratios since 3:1 to 10:1). 
Concentrations of haloperidol measured by HPLC 
are from 0.0308 to 0.0637 mg mL-1 and in case of 
midazolam, it ranged are from 0.1842 to 0.7305 mg mL-1 
covering a wide broad of possible admixtures for the 
clinical use of both drugs (Table IV).
In case of midazolam and haloperidol, first of all, 
the appearance of the admixtures was shown by visual 
inspection, checking the no apparition of turbidity, 
precipitate or colour change. All the prepared admixtures 
have good appearance during the studied days.
Thus, the study of the turbidity measurement was 
done. In Table II, it is possible to check the evolution 
of the turbidity in function of the time. This analysis 
was done because if a precipitate appears, the value 
of the turbidity will increase strongly. In our case, 
most of the studied admixtures have regular values, 
accepting a variance due of the instrument of 0.01. 
Some of the admixtures have an incongruent value, 
with lower values than the rest of the values of the same 
admixture in function of the time. However, the global 
variance does not show any significant trend increase in 
any of the studied admixtures. Furthermore, turbidity 
measurement was done as an initial test to establish the 
whether there is an apparition of precipitate or none and 
the determinations will be corroborated with the other 
two experimental techniques.
The determination of the pH can give another 
idea about a possible change in the composition of the 
admixtures. Table III shows the determination of this 
parameter after the preparation of the admixtures and its 
evolution until 168 hours (seven days). In eight of the 
prepared admixtures, variance of the pH values was lower 
than 0.07 units of pH. Just in case of sample MIDHAL7 the 
variance was 0.13 units. This little variance corresponds 
with no remarkable change in the compositions of the 
admixtures.
However, the main experimental employed 
technique was the HPLC by following a validated assay 
by the FDA (2001) and EMA (2011) requirements. In the 
Supporting Information, all the relevant information about 
specificity, selectivity, linearity, short-term stability and 
forced degradation studies is presented. All the studied 
parameters were found satisfactory. 
The obtained data by the HPLC determination 
are presented in Table IV. In the first two columns, the 
concentration of haloperidol and midazolam, respectively 
in each admixture are presented. Then, for the rest of the 
day the percentage of remaining drugs are presented. The 
acceptable concentration range for the drugs is from 90% 
to 110%. In our admixtures, all the studied samples are 
inside this range until the fourth day. 
On the seventh day, the concentration is lessen in 
some of the samples. Three of the seven admixtures stored 
at room temperature showed concentrations of one or both 
drugs lower than the 90% (MIDHAL1, MIDHAL3 and 
MIDHAL5). Then, the chemical stability can be assigned 
as a maximum of 96 hours when samples are stored at 
TABLE IV - Mean percentages values of drugs concentrations at time zero and remaining percentages in the admixtures at different 
times
Sample
Time (hours)
0 24 72 96 168
Hal* 
(mg mL-1)
Mid** 
(mg mL-1)
Hal 
(%)
Mid 
(%)
Hal 
(%)
Mid 
(%)
Hal 
(%)
Mid 
(%)
Hal 
(%)
Mid 
(%)
MIDHAL1 0.0347 0.1906 96.18 94.38 102.82 107.68 93.13 109.31 101.67 68.91
MIDHAL2 0.0308 0.3883 99.29 97.50 102.86 106.24 101.33 108.26 108.96 102.77
MIDHAL3 0.0335 0.4889 108.58 100.42 96.99 101.19 91.35 98.86 88.42 86.52
MIDHAL4 0.0637 0.4053 96.69 96.32 98.74 103.51 101.22 106.85 93.74 91.92
MIDHAL5 0.0547 0.6533 104.73 103.31 106.77 107.98 105.12 104.86 103.99 103.25
MIDHAL6 0.0331 0.1842 107.22 103.52 95.54 101.28 101.56 108.62 107.41 72.14
MIDHAL7 0.0628 0.7305 101.92 98.99 97.51 99.25 92.32 93.83 91.56 95.78
MIDHAL8 0.0598 0.6648 96.34 94.56 99.43 102.69 102.34 105.77 93.12 98.43
MIDHAL9 0.0621 0.7137 104.83 102.50 96.17 98.28 101.62 103.29 101.06 108.59
Hal* = Haloperidol; Mid**= Midazolam.
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20 ºC. There is not a significant difference in function of 
the diluent. 
The two refrigerated samples (MIDHAL8 and 
MIDHAL9) showed a larger chemical stability and they 
are stable even on the seventh day.
We have found a lower value than the previously 
reported stability (Martínez-Gómez et al., 2007) for the 
binary blends. Midazolam and haloperidol admixtures do 
not need really larger stabilities to be used for perfusion. 
Then, four days can be enough for palliative sedation.
Finally,  our Pharmacy Service follows the 
microbiological risk matrix (Rosales Cabrera, López 
Cabezas, García Salom, 2014) to minimize the possible 
risk by microbiological contamination. In case of prepared 
admixtures of midazolam and haloperidol stored at room 
temperature, the assigned maximum stability is 48 hours. 
This value is higher in case of refrigerated samples 
until fourteen days. Then, midazolam and haloperidol 
admixtures stored at 20 ºC can be considered stable until 
48 hours after their preparation. In case of home patients 
under sedative treatment, samples should be refrigerated 
after the preparation until its use to increase this range of 
stability until the seventh day.
In case of the samples stored at room temperature 
acceptable chemical concentrations are obtained until the 
fourth day. However, by the microbiological risk matrix 
assignment 48 hours of stability can be assured. This time 
is enough for hospitalized patients who need midazolam 
and haloperidol admixtures for palliative sedation.
When samples are stored refrigerated, the adequate 
values of concentrations are obtained until the seventh day. 
In addition, seven days are adequate for microbiological 
stability. Then, for home patients, samples should be 
refrigerated after their preparation.
A validated method following the agencies 
requirements was followed with good results of precision, 
accuracy and stability of the working solutions to quantify 
midazolam and haloperidol admixtures.
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